用于识别新发和复发性癌症的可靠生物标志物。
Reliable Biomarkers to Identify New and Recurrent Cancer.
作者信息
Sauter Edward R
机构信息
Department of Surgery, Hartford Hospital and University of Connecticut School of Medicine, Hartford, USA.
出版信息
Eur J Breast Health. 2017 Oct 1;13(4):162-167. doi: 10.5152/ejbh.2017.3635. eCollection 2017 Oct.
Abstract
Breast cancer is the most frequent cancer detected throughout both the developing and the developed world. Its incidence is on the rise in the developing world. Great strides have been made in developing biomarkers to guide therapy for women diagnosed with breast cancer. Far fewer advances have occurred with biomarker development for the early diagnosis of breast cancer. Standard screening for new and recurrent breast cancer involves clinical breast exam and breast imaging. There are no Food and Drug Administration (FDA) approved noninvasive body fluid tests for the early detection of new or recurrent breast cancer. Promising biomarker approaches include multianalyte testing of tissue for individuals diagnosed with breast cancer and body fluid analysis for both at risk women and to monitor individuals after treatment.
摘要
乳腺癌是在发展中国家和发达国家中检出率最高的癌症。在发展中国家，其发病率呈上升趋势。在开发用于指导乳腺癌确诊女性治疗的生物标志物方面已取得了长足进展。而在用于乳腺癌早期诊断的生物标志物开发方面进展则少得多。对新发和复发性乳腺癌的标准筛查包括临床乳腺检查和乳腺成像。目前尚无美国食品药品监督管理局（FDA）批准的用于早期检测新发或复发性乳腺癌的非侵入性体液检测方法。有前景的生物标志物方法包括对乳腺癌确诊个体进行组织多分析物检测，以及对高危女性进行体液分析并在治疗后监测个体。
相似文献
1
Reliable Biomarkers to Identify New and Recurrent Cancer.用于识别新发和复发性癌症的可靠生物标志物。
Eur J Breast Health. 2017 Oct 1;13(4):162-167. doi: 10.5152/ejbh.2017.3635. eCollection 2017 Oct.
2
Resolving breast cancer heterogeneity by searching reliable protein cancer biomarkers in the breast fluid secretome.通过在乳腺液分泌组中寻找可靠的蛋白质癌症生物标志物来解决乳腺癌异质性。
BMC Cancer. 2013 Jul 12;13:344. doi: 10.1186/1471-2407-13-344.
3
Proteomic Analysis of Inflammatory Biomarkers Associated With Breast Cancer Recurrence.与乳腺癌复发相关的炎症生物标志物的蛋白质组学分析
Mil Med. 2020 Jan 7;185(Suppl 1):669-675. doi: 10.1093/milmed/usz254.
5
Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer.评估乳头抽吸液作为早期乳腺癌诊断工具的价值。
Clin Proteomics. 2018 Jan 11;15:3. doi: 10.1186/s12014-017-9179-4. eCollection 2018.
6
The future of blood-based biomarkers for the early detection of breast cancer.用于早期检测乳腺癌的基于血液的生物标志物的未来。
Eur J Cancer. 2018 Mar;92:54-68. doi: 10.1016/j.ejca.2017.12.025. Epub 2018 Feb 6.
7
Screening mammography for women aged 40 to 49 years at average risk for breast cancer: an evidence-based analysis.针对40至49岁患乳腺癌平均风险女性的乳腺钼靶筛查：一项基于证据的分析。
Ont Health Technol Assess Ser. 2007;7(1):1-32. Epub 2007 Jan 1.
8
Biomarker Reproducibility Challenge: A Review of Non-Nucleotide Biomarker Discovery Protocols from Body Fluids in Breast Cancer Diagnosis.生物标志物再现性挑战：乳腺癌诊断中体液非核苷酸生物标志物发现方案综述
Cancers (Basel). 2023 May 16;15(10):2780. doi: 10.3390/cancers15102780.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
Recent Discoveries of Macromolecule- and Cell-Based Biomarkers and Therapeutic Implications in Breast Cancer.乳腺癌中基于大分子和细胞的生物标志物的最新发现及治疗意义。
Int J Mol Sci. 2021 Jan 10;22(2):636. doi: 10.3390/ijms22020636.
引用本文的文献
1
Advancements in non-invasive biomarkers for detection and monitoring of breast cancer recurrence.用于检测和监测乳腺癌复发的非侵入性生物标志物的进展。
Sci Prog. 2025 Jul-Sep;108(3):368504251362350. doi: 10.1177/00368504251362350. Epub 2025 Aug 19.
2
Cytokeratin expression in breast cancer: from mechanisms, progression, diagnosis, and prognosis to therapeutic implications.细胞角蛋白在乳腺癌中的表达：从机制、进展、诊断、预后到治疗意义
Mol Cell Oncol. 2025 Jul 1;12(1):2526230. doi: 10.1080/23723556.2025.2526230. eCollection 2025.
3
Non-Coding RNAs in Breast Cancer: Diagnostic and Therapeutic Implications.乳腺癌中的非编码RNA：诊断和治疗意义
Int J Mol Sci. 2024 Dec 26;26(1):127. doi: 10.3390/ijms26010127.
4
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.靶向催产素受体治疗乳腺癌：肽示踪剂的新领域。
J Med Chem. 2024 Feb 8;67(3):1625-1640. doi: 10.1021/acs.jmedchem.3c01089. Epub 2024 Jan 18.
5
Non-Coding RNAs in Human Cancer and Other Diseases: Overview of the Diagnostic Potential.非编码 RNA 在人类癌症和其他疾病中的作用：诊断潜力概述。
Int J Mol Sci. 2023 Nov 11;24(22):16213. doi: 10.3390/ijms242216213.
6
Identifying patients suitable for targeted adjuvant therapy: advances in the field of developing biomarkers for tumor recurrence following irradiation.识别适合靶向辅助治疗的患者：放疗后肿瘤复发生物标志物开发领域的进展。
Expert Rev Precis Med Drug Dev. 2023;8(1):33-42. doi: 10.1080/23808993.2023.2276927. Epub 2023 Nov 16.
7
The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients.液滴数字PCR在乳腺癌患者循环肿瘤DNA分析中的临床应用
Diagnostics (Basel). 2022 Dec 5;12(12):3042. doi: 10.3390/diagnostics12123042.
8
THOR is a targetable epigenetic biomarker with clinical implications in breast cancer.THOR 是一种有靶向性的表观遗传生物标志物，对乳腺癌具有临床意义。
Clin Epigenetics. 2022 Dec 18;14(1):178. doi: 10.1186/s13148-022-01396-3.
9
Classic and New Markers in Diagnostics and Classification of Breast Cancer.乳腺癌诊断与分类中的经典和新型标志物
Cancers (Basel). 2022 Nov 5;14(21):5444. doi: 10.3390/cancers14215444.
10
A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer.两种癌症的故事：乳腺癌和前列腺癌的当前简要概述
Cancers (Basel). 2022 Jun 15;14(12):2954. doi: 10.3390/cancers14122954.
本文引用的文献
1
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.使用生物标志物指导转移性乳腺癌女性患者的全身治疗决策：美国临床肿瘤学会临床实践指南
J Oncol Pract. 2015 Nov;11(6):514-516. doi: 10.1200/JOP.2015.005215.
2
70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.70 基因特征作为早期乳腺癌治疗决策的辅助手段。
N Engl J Med. 2016 Aug 25;375(8):717-29. doi: 10.1056/NEJMoa1602253.
3
Breast Cancer Genetics for the Surgeon: An Update on Causes and Testing Options.外科医生的乳腺癌遗传学：病因及检测选择的最新进展
J Am Coll Surg. 2016 May;222(5):906-14. doi: 10.1016/j.jamcollsurg.2016.01.005. Epub 2016 Jan 22.
4
Breast Cancer Screening for Women at Average Risk: 2015 Guideline Update From the American Cancer Society.平均风险女性的乳腺癌筛查：美国癌症协会2015年指南更新
JAMA. 2015 Oct 20;314(15):1599-614. doi: 10.1001/jama.2015.12783.
5
Development and verification of the PAM50-based Prosigna breast cancer gene signature assay.基于PAM50的Prosigna乳腺癌基因特征检测法的开发与验证
BMC Med Genomics. 2015 Aug 22;8:54. doi: 10.1186/s12920-015-0129-6.
6
Gene-panel sequencing and the prediction of breast-cancer risk.基因panel测序与乳腺癌风险预测
N Engl J Med. 2015 Jun 4;372(23):2243-57. doi: 10.1056/NEJMsr1501341. Epub 2015 May 27.
7
The validation and clinical implementation of BRCAplus: a comprehensive high-risk breast cancer diagnostic assay.BRCAplus的验证与临床应用：一种全面的高危乳腺癌诊断检测方法
PLoS One. 2014 May 15;9(5):e97408. doi: 10.1371/journal.pone.0097408. eCollection 2014.
8
Tumour cell heterogeneity maintained by cooperating subclones in Wnt-driven mammary cancers.Wnt 驱动型乳腺癌中合作亚克隆维持的肿瘤细胞异质性。
Nature. 2014 Apr 3;508(7494):113-7. doi: 10.1038/nature13187.
9
Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?循环HER2细胞外结构域：所有乳腺癌患者预后价值的特异性定量生物标志物？
Biomark Cancer. 2013 Aug 12;5:31-9. doi: 10.4137/BIC.S12389.
10
Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.肿瘤蛋白 p53（TP53）检测与李-佛美尼综合征：临床应用现状与未来方向。
Mol Diagn Ther. 2013 Feb;17(1):31-47. doi: 10.1007/s40291-013-0020-0.
Zotero 插件